Commentary: antibodies reacting with the infliximab Fab portion--something new? Authors' reply.
Department of Infectious Diseases and Rheumatology, Institute for Inflammation Research, University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Claus.Henrik.Nielsen@regionh.dk
C H
CH
Nielsen
C
C
Steenholdt
Y
Y
Palarasah
K
K
Bendtzen
A
A
Teisner
J
J
Brynskov
B
B
Teisner
D000911:Antibodies, Monoclonal / Q000276:immunology*; D005260:Female; D005765:Gastrointestinal Agents / Q000276:immunology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood*; D015212:Inflammatory Bowel Diseases / Q000276:immunology*; D008297:Male
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G